Cerevel Therapeutics (NASDAQ:CERE) Coverage Initiated at Piper Sandler

Piper Sandler initiated coverage on shares of Cerevel Therapeutics (NASDAQ:CERE – Free Report) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $33.00 price objective on the biotechnology company’s stock. CERE has been the subject of a number of other reports. Bank of America […]

Related Keywords

United States ,America ,Pauld Burgess ,Piper Sandler ,Ronaldc Renaud Jr ,Pricet Rowe Associates Inc ,Cerevel Therapeutics Holdings Inc ,Cerevel Therapeutics Company Profile ,Securities Exchange Commission ,Perceptive Advisors ,Morgan Stanley ,Vanguard Group Inc ,Blackrock Inc ,Cerevel Therapeutics ,Free Report ,Marketbeat Ratings ,Moderate Buy ,Get Free Report ,Exchange Commission ,State Street Corp ,Street Corp ,Therapeutics Holdings ,Cerevel Therapeutics Daily ,Nasdaq Cere ,Racere ,Medical ,15677310 ,Initiated Coverage ,